Micafungin
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Invasive Aspergillosis
Conditions
Invasive Aspergillosis
Trial Timeline
Mar 1, 2014 → Jun 26, 2015
NCT ID
NCT02646774About Micafungin
Micafungin is a approved stage product being developed by Astellas Pharma for Invasive Aspergillosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02646774. Target conditions include Invasive Aspergillosis.
What happened to similar drugs?
3 of 20 similar drugs in Invasive Aspergillosis were approved
Approved (3) Terminated (1) Active (16)
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
20 competing products in Invasive Aspergillosis